{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T21:54:30Z","timestamp":1790546070342,"version":"4.1.0"},"reference-count":72,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["R35HL135816"],"award-info":[{"award-number":["R35HL135816"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["R01 HL105487"],"award-info":[{"award-number":["R01 HL105487"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["P30 DK072482"],"award-info":[{"award-number":["P30 DK072482"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["5UL1 RR025777"],"award-info":[{"award-number":["5UL1 RR025777"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["CLANCY09Y0"],"award-info":[{"award-number":["CLANCY09Y0"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["R464-CF"],"award-info":[{"award-number":["R464-CF"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["SORSCH15RO"],"award-info":[{"award-number":["SORSCH15RO"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","bmn.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Pharmacology"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1016\/j.coph.2017.09.013","type":"journal-article","created":{"date-parts":[[2017,11,10]],"date-time":"2017-11-10T11:04:07Z","timestamp":1510311847000},"page":"132-139","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":47,"special_numbering":"C","title":["The therapeutic potential of CFTR modulators for COPD and other airway diseases"],"prefix":"10.1016","volume":"34","author":[{"given":"George M","family":"Solomon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lianwu","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven M","family":"Rowe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James F","family":"Collawn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.coph.2017.09.013_bib0005","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1378\/chest.10-2948","article-title":"The chronic bronchitic phenotype of COPD: an analysis of the COPDGene study","volume":"140","author":"Kim","year":"2011","journal-title":"Chest"},{"key":"10.1016\/j.coph.2017.09.013_bib0010","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1164\/rccm.201210-1843CI","article-title":"Chronic bronchitis and chronic obstructive pulmonary disease","volume":"187","author":"Kim","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.coph.2017.09.013_bib0015","doi-asserted-by":"crossref","first-page":"667","DOI":"10.3109\/15412555.2013.827166","article-title":"Severe chronic bronchitis in advanced emphysema increases mortality and hospitalizations","volume":"10","author":"Kim","year":"2013","journal-title":"COPD"},{"key":"10.1016\/j.coph.2017.09.013_sbref0020","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.ccm.2015.11.003","article-title":"Acquired cystic fibrosis transmembrane conductance regulator dysfunction in chronic bronchitis and other diseases of mucus clearance","volume":"37","author":"Raju","year":"2016","journal-title":"Clin Chest Med"},{"key":"10.1016\/j.coph.2017.09.013_bib0025","doi-asserted-by":"crossref","first-page":"e39809","DOI":"10.1371\/journal.pone.0039809","article-title":"A pharmacologic approach to acquired cystic fibrosis transmembrane conductance regulator dysfunction in smoking related lung disease","volume":"7","author":"Sloane","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.coph.2017.09.013_sbref0030","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1164\/rccm.200508-1330OC","article-title":"Cystic fibrosis transmembrane conductance regulator function is suppressed in cigarette smokers","volume":"173","author":"Cantin","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.coph.2017.09.013_sbref0035","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1378\/chest.13-0274","article-title":"Acquired cystic fibrosis transmembrane conductance regulator dysfunction in the lower airways in COPD","volume":"144","author":"Dransfield","year":"2013","journal-title":"Chest"},{"key":"10.1016\/j.coph.2017.09.013_bib0040","doi-asserted-by":"crossref","first-page":"e109725","DOI":"10.1371\/journal.pone.0109725","article-title":"Correlation of apical fluid-regulating channel proteins with lung function in human COPD lungs","volume":"9","author":"Zhao","year":"2014","journal-title":"PLOS ONE"},{"key":"10.1016\/j.coph.2017.09.013_bib0045","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/1465-9921-15-25","article-title":"Acquired defects in CFTR-dependent beta-adrenergic sweat secretion in chronic obstructive pulmonary disease","volume":"15","author":"Courville","year":"2014","journal-title":"Respir Res"},{"key":"10.1016\/j.coph.2017.09.013_bib0050","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1164\/rccm.201502-0396LE","article-title":"Recovery of acquired cystic fibrosis transmembrane conductance regulator (CFTR) dysfunction following smoking cessation","volume":"192","author":"Courville","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.coph.2017.09.013_bib0055","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1093\/toxsci\/kfq101","article-title":"Cadmium regulates the expression of the CFTR chloride channel in human airway epithelial cells","volume":"116","author":"Rennolds","year":"2010","journal-title":"Toxicol Sci"},{"key":"10.1016\/j.coph.2017.09.013_sbref0060","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1164\/rccm.201304-0733OC","article-title":"Cigarette smoke induces systemic defects in cystic fibrosis transmembrane conductance regulator function","volume":"188","author":"Raju","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.coph.2017.09.013_bib0065","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.freeradbiomed.2016.06.017","article-title":"Nicotine exposure induces bronchial epithelial cell apoptosis and senescence via ROS mediated autophagy-impairment","volume":"97","author":"Bodas","year":"2016","journal-title":"Free Radic Biol Med"},{"key":"10.1016\/j.coph.2017.09.013_bib0070","doi-asserted-by":"crossref","first-page":"7671","DOI":"10.1074\/jbc.M113.545137","article-title":"Cigarette smoke-induced Ca2+ release leads to cystic fibrosis transmembrane conductance regulator (CFTR) dysfunction","volume":"289","author":"Rasmussen","year":"2014","journal-title":"J Biol Chem"},{"key":"10.1016\/j.coph.2017.09.013_bib0075","doi-asserted-by":"crossref","first-page":"L1398","DOI":"10.1152\/ajplung.00272.2015","article-title":"Will chronic e-cigarette use cause lung disease?","volume":"309","author":"Rowell","year":"2015","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"10.1016\/j.coph.2017.09.013_sbref0080","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1096\/fj.11-192377","article-title":"Cigarette smoke exposure induces CFTR internalization and insolubility, leading to airway surface liquid dehydration","volume":"26","author":"Clunes","year":"2012","journal-title":"FASEB J"},{"key":"10.1016\/j.coph.2017.09.013_bib0085","doi-asserted-by":"crossref","first-page":"e8157","DOI":"10.1371\/journal.pone.0008157","article-title":"Smoking is associated with shortened airway cilia","volume":"4","author":"Leopold","year":"2009","journal-title":"PLoS ONE"},{"key":"10.1016\/j.coph.2017.09.013_sbref0090","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1164\/rccm.201205-0875OC","article-title":"Neutrophil elastase degrades cystic fibrosis transmembrane conductance regulator via calpains and disables channel function in vitro and in vivo","volume":"187","author":"Le Gars","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.coph.2017.09.013_bib0095","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1056\/NEJM199201303260504","article-title":"Predominant TH2-like bronchoalveolar T-lymphocyte population in atopic asthma","volume":"326","author":"Robinson","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coph.2017.09.013_bib0100","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1165\/ajrcmb.13.6.7576713","article-title":"Analysis of respiratory mucus glycoproteins in asthma: a detailed study from a patient who died in status asthmaticus","volume":"13","author":"Sheehan","year":"1995","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10.1016\/j.coph.2017.09.013_bib0105","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1056\/NEJMra0910061","article-title":"Airway mucus function and dysfunction","volume":"363","author":"Fahy","year":"2010","journal-title":"N Engl J Med"},{"issue":"Suppl. 1","key":"10.1016\/j.coph.2017.09.013_bib0110","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1159\/000337801","article-title":"Neutrophilic inflammation in severe asthma","volume":"158","author":"Nakagome","year":"2012","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.coph.2017.09.013_bib0115","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1097\/MCP.0b013e32831da8d3","article-title":"Mucus hypersecretion in asthma: causes and effects","volume":"15","author":"Evans","year":"2009","journal-title":"Curr Opin Pulm Med"},{"key":"10.1016\/j.coph.2017.09.013_bib0120","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1097\/SMJ.0b013e31802fa16f","article-title":"The impact of bronchiectasis in clinical presentation of asthma","volume":"100","author":"Oguzulgen","year":"2007","journal-title":"South Med J"},{"key":"10.1016\/j.coph.2017.09.013_bib0125","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1155\/2012\/267251","article-title":"The role of CFTR mutations in asthma","volume":"19","author":"Sandford","year":"2012","journal-title":"Can Respir J"},{"key":"10.1016\/j.coph.2017.09.013_bib0130","first-page":"469","article-title":"Association of CFTR gene mutation with bronchial asthma","volume":"135","author":"Maurya","year":"2012","journal-title":"Indian J Med Res"},{"key":"10.1016\/j.coph.2017.09.013_bib0135","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1186\/rr82","article-title":"\u2018CFTR-opathies\u2019: disease phenotypes associated with cystic fibrosis transmembrane regulator gene mutations","volume":"2","author":"Noone","year":"2001","journal-title":"Respir Res"},{"key":"10.1016\/j.coph.2017.09.013_bib0140","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1155\/2012\/546702","article-title":"Cystic fibrosis transmembrane conductance regulator gene abnormalities in patients with asthma and recurrent neutrophilic bronchitis","volume":"19","author":"Goodwin","year":"2012","journal-title":"Can Respir J"},{"key":"10.1016\/j.coph.2017.09.013_bib0145","doi-asserted-by":"crossref","first-page":"2695","DOI":"10.1016\/j.yexcr.2007.02.035","article-title":"Interleukin-13 interferes with CFTR and AQP5 expression and localization during human airway epithelial cell differentiation","volume":"313","author":"Skowron-zwarg","year":"2007","journal-title":"Exp Cell Res"},{"key":"10.1016\/j.coph.2017.09.013_bib0150","doi-asserted-by":"crossref","first-page":"L226","DOI":"10.1152\/ajplung.00311.2001","article-title":"Interleukin-13 induces a hypersecretory ion transport phenotype in human bronchial epithelial cells","volume":"282","author":"Danahay","year":"2002","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"10.1016\/j.coph.2017.09.013_bib0155","doi-asserted-by":"crossref","first-page":"839","DOI":"10.4049\/jimmunol.168.2.839","article-title":"IL-4 is a potent modulator of ion transport in the human bronchial epithelium in vitro","volume":"168","author":"Galietta","year":"2002","journal-title":"J Immunol"},{"key":"10.1016\/j.coph.2017.09.013_bib0160","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1183\/09031936.00181209","article-title":"Allergic airway inflammation induces a pro-secretory epithelial ion transport phenotype in mice","volume":"36","author":"Anagnostopoulou","year":"2010","journal-title":"Eur Respir J"},{"key":"10.1016\/j.coph.2017.09.013_bib0165","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.jcf.2015.10.011","article-title":"Non-allergic asthma as a CFTR-related disorder","volume":"15","author":"Schulz","year":"2016","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.coph.2017.09.013_bib0170","doi-asserted-by":"crossref","first-page":"225","DOI":"10.2174\/1389450111314020007","article-title":"Antioxidants and mucolytics in COPD management: when (if ever) and in whom?","volume":"14","author":"Hillas","year":"2013","journal-title":"Curr Drug Targets"},{"key":"10.1016\/j.coph.2017.09.013_bib0175","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.ccm.2007.02.014","article-title":"Pathogenesis of bronchiectasis","volume":"28","author":"Morrissey","year":"2007","journal-title":"Clin Chest Med"},{"issue":"Suppl. 2","key":"10.1016\/j.coph.2017.09.013_bib0180","first-page":"S123","article-title":"Neutrophil fates in bronchiectasis and alpha-1 antitrypsin deficiency","volume":"13","author":"Russell","year":"2016","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.coph.2017.09.013_bib0185","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.jcf.2015.02.012","article-title":"Should diffuse bronchiectasis still be considered a CFTR-related disorder?","volume":"14","author":"Bergougnoux","year":"2015","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.coph.2017.09.013_bib0190","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1164\/rccm.200909-1434OC","article-title":"Cystic fibrosis transmembrane conductance regulator channel dysfunction in non-cystic fibrosis bronchiectasis","volume":"181","author":"Bienvenu","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.coph.2017.09.013_bib0195","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1164\/rccm.200703-456SO","article-title":"Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: gold executive summary","volume":"176","author":"Rabe","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"issue":"Suppl.","key":"10.1016\/j.coph.2017.09.013_bib0200","doi-asserted-by":"crossref","first-page":"121S","DOI":"10.1378\/chest.121.5_suppl.121S","article-title":"COPD: Epidemiology, prevalence, morbidity and mortality, and disease heterogeneity","volume":"121","author":"Mannino","year":"2002","journal-title":"Chest"},{"key":"10.1016\/j.coph.2017.09.013_bib0205","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1001\/jama.2008.717","article-title":"Inhaled corticosteroids in patients with stable chronic obstructive pulmonary disease: a systematic review and meta-analysis","volume":"300","author":"Drummond","year":"2008","journal-title":"JAMA"},{"key":"10.1016\/j.coph.2017.09.013_bib0210","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1056\/NEJMoa063070","article-title":"Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease","volume":"356","author":"Calverley","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coph.2017.09.013_bib0215","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1056\/NEJMoa0805800","article-title":"A 4-year trial of tiotropium in chronic obstructive pulmonary disease","volume":"359","author":"Tashkin","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coph.2017.09.013_bib0220","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1183\/09031936.00193908","article-title":"Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: torch study results","volume":"34","author":"Crim","year":"2009","journal-title":"Eur Respir J"},{"key":"10.1016\/j.coph.2017.09.013_bib0225","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1097\/MCP.0b013e328334c085","article-title":"Risk of pneumonia associated with long-term use of inhaled corticosteroids in chronic obstructive pulmonary disease: a critical review and update","volume":"16","author":"Singh","year":"2010","journal-title":"Curr Opin Pulm Med"},{"key":"10.1016\/j.coph.2017.09.013_bib0230","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1016\/S0140-6736(05)66456-2","article-title":"Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (bronchitis randomized on NAC cost-utility study, BRONCUS): a randomised placebo-controlled trial","volume":"365","author":"Decramer","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.coph.2017.09.013_bib0235","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1016\/S0140-6736(08)60869-7","article-title":"Effect of carbocisteine on acute exacerbation of chronic obstructive pulmonary disease (peace study): a randomised placebo-controlled study","volume":"371","author":"Zheng","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.coph.2017.09.013_bib0240","first-page":"CD001287","article-title":"Mucolytic agents for chronic bronchitis or chronic obstructive pulmonary disease","volume":"3","author":"Poole","year":"2006","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.coph.2017.09.013_bib0245","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1001\/archinte.160.11.1683","article-title":"Obstructive lung disease and low lung function in adults in the United States: data from the national health and nutrition examination survey, 1988\u20131994","volume":"160","author":"Mannino","year":"2000","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.coph.2017.09.013_bib0250","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1378\/chest.07-0843","article-title":"Oral corticosteroid therapy in cystic fibrosis patients hospitalized for pulmonary exacerbation: a pilot study","volume":"132","author":"Dovey","year":"2007","journal-title":"Chest"},{"key":"10.1016\/j.coph.2017.09.013_bib0255","doi-asserted-by":"crossref","first-page":"693","DOI":"10.2147\/COPD.S22896","article-title":"A pilot study of the impact of high-frequency chest wall oscillation in chronic obstructive pulmonary disease patients with mucus hypersecretion","volume":"6","author":"Chakravorty","year":"2011","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"10.1016\/j.coph.2017.09.013_bib0260","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1001\/jama.290.13.1749","article-title":"Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial","volume":"290","author":"Saiman","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.coph.2017.09.013_bib0265","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1056\/NEJMoa1104623","article-title":"Azithromycin for prevention of exacerbations of COPD","volume":"365","author":"Albert","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coph.2017.09.013_bib0270","first-page":"301","article-title":"Treatment of cystic fibrosis with CFTR modulators","volume":"70","author":"Tummler","year":"2016","journal-title":"Pneumologie"},{"issue":"Suppl. 40","key":"10.1016\/j.coph.2017.09.013_bib0275","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1002\/ppul.23240","article-title":"Breakthrough therapies: cystic fibrosis (CF) potentiators and correctors","volume":"50","author":"Solomon","year":"2015","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.coph.2017.09.013_sbref0280","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1165\/rcmb.2016-0226OC","article-title":"The cystic fibrosis transmembrane conductance regulator potentiator ivacaftor augments mucociliary clearance abrogating cystic fibrosis transmembrane conductance regulator inhibition by cigarette smoke","volume":"56","author":"Raju","year":"2017","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10.1016\/j.coph.2017.09.013_sbref0285","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1164\/rccm.201404-0703OC","article-title":"Clinical mechanism of the CFTR potentiator ivacaftor in G551D-mediated cystic fibrosis","volume":"190","author":"Rowe","year":"2014","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.coph.2017.09.013_sbref0290","doi-asserted-by":"crossref","first-page":"18825","DOI":"10.1073\/pnas.0904709106","article-title":"Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, Vx-770","volume":"106","author":"Van Goor","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.coph.2017.09.013_sbref0295","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jcf.2013.06.008","article-title":"Effect of ivacaftor on CFTR forms with missense mutations associated with defects in protein processing or function","volume":"13","author":"Van Goor","year":"2014","journal-title":"J Cyst Fibrosis"},{"key":"10.1016\/j.coph.2017.09.013_bib0300","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/S0165-6147(99)01386-3","article-title":"Molecular pharmacology of the CFTR Cl\u2212 channel","volume":"20","author":"Hwang","year":"1999","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.coph.2017.09.013_bib0305","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/nrd2780","article-title":"Chloride channels as drug targets","volume":"8","author":"Verkman","year":"2009","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.coph.2017.09.013_bib0310","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1085\/jgp.20028599","article-title":"Regulation of murine airway surface liquid volume by CFTR and Ca2+-activated Cl\u2212 conductances","volume":"120","author":"Tarran","year":"2002","journal-title":"J Gen Physiol"},{"key":"10.1016\/j.coph.2017.09.013_bib0315","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1513\/pats.2306014","article-title":"Regulation of airway surface liquid volume and mucus transport by active ion transport","volume":"1","author":"Tarran","year":"2004","journal-title":"Proc Am Thorac Soc"},{"issue":"Suppl. 2","key":"10.1016\/j.coph.2017.09.013_bib0320","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.jcf.2004.05.029","article-title":"Measurements of airway surface liquid height and mucus transport by fluorescence microscopy, and of ion composition by X-ray microanalysis","volume":"3","author":"Roomans","year":"2004","journal-title":"J Cyst Fibrosis"},{"key":"10.1016\/j.coph.2017.09.013_bib0325","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1172\/JCI2687","article-title":"Coordinated clearance of periciliary liquid and mucus from airway surfaces","volume":"102","author":"Matsui","year":"1998","journal-title":"J Clin Invest"},{"key":"10.1016\/j.coph.2017.09.013_bib0330","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1513\/pats.200703-042BR","article-title":"Mucociliary clearance as an outcome measure for cystic fibrosis clinical research","volume":"4","author":"Donaldson","year":"2007","journal-title":"Proc Am Thorac Soc"},{"key":"10.1016\/j.coph.2017.09.013_sbref0335","doi-asserted-by":"crossref","first-page":"e32","DOI":"10.1016\/S2213-2600(16)30047-9","article-title":"Pilot evaluation of ivacaftor for chronic bronchitis","volume":"4","author":"Solomon","year":"2016","journal-title":"Lancet Respir Med"},{"issue":"Suppl. 2","key":"10.1016\/j.coph.2017.09.013_bib0340","first-page":"S169","article-title":"Therapeutic approaches to acquired cystic fibrosis transmembrane conductance regulator dysfunction in chronic bronchitis","volume":"13","author":"Solomon","year":"2016","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.coph.2017.09.013_bib0345","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/1465-9921-12-18","article-title":"Reduction of exacerbations by the PDE4 inhibitor roflumilast\u2014the importance of defining different subsets of patients with COPD","volume":"12","author":"Rennard","year":"2011","journal-title":"Respir Res"},{"key":"10.1016\/j.coph.2017.09.013_bib0350","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/S0140-6736(09)61252-6","article-title":"Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials","volume":"374","author":"Fabbri","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.coph.2017.09.013_bib0355","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1165\/rcmb.2013-0228OC","article-title":"Cystic fibrosis transmembrane conductance regulator activation by roflumilast contributes to therapeutic benefit in chronic bronchitis","volume":"50","author":"Lambert","year":"2014","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10.1016\/j.coph.2017.09.013_bib0360","doi-asserted-by":"crossref","first-page":"L1068","DOI":"10.1152\/ajplung.00395.2014","article-title":"Roflumilast combined with adenosine increases mucosal hydration in human airway epithelial cultures after cigarette smoke exposure","volume":"308","author":"Tyrrell","year":"2015","journal-title":"Am J Physiol Lung Cell Mol Physiol"}],"container-title":["Current Opinion in Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471489217300486?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471489217300486?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,26]],"date-time":"2018-08-26T00:24:50Z","timestamp":1535243090000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1471489217300486"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6]]},"references-count":72,"alternative-id":["S1471489217300486"],"URL":"https:\/\/doi.org\/10.1016\/j.coph.2017.09.013","relation":{},"ISSN":["1471-4892"],"issn-type":[{"value":"1471-4892","type":"print"}],"subject":[],"published":{"date-parts":[[2017,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The therapeutic potential of CFTR modulators for COPD and other airway diseases","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.coph.2017.09.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}